Q-Line Biotech IPO is one of the major SME IPOs in the healthcare and diagnostic sector in 2026. The company has shown strong revenue growth over the years and operates in the rapidly growing in-vitro diagnostics (IVD) and medical equipment industry.
The IPO will open on May 21, 2026, and close on May 25, 2026. The company plans to raise approximately ₹214.48 crores through a book build issue and will list on NSE SME. In this detailed IPO Updates review, we will cover the Q-Line Biotech IPO date, GMP, review, price band, allotment details, subscription, financials, strengths, risks, and whether investors should apply or avoid this IPO.(ipo updates).
| IPO Open Thu, May 21, 2026 | IPO Close Mon, May 25, 2026 | Issue Price ₹343 per share | Market Cap (Pre-IPO) To be declared |
Q-Line Biotech IPO Details
| Particulars | Details |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹326 to ₹343 Per Share |
| Issue Size | Approx ₹214.48 Crores |
| Fresh Issue | 62,53,200 Equity Shares |
| IPO Type | Book Build Issue |
| Listing Exchange | NSE SME |
| Allotment Date | May 26, 2026 |
| Listing Date | May 29, 2026 |
About Q-Line Biotech Limited
Q-Line Biotech Limited was incorporated in 2013 and operates in the healthcare and diagnostic industry. The company manufactures and supplies:
- In-Vitro Diagnostic (IVD) Products
- Diagnostic Equipment
- Pathology Instruments
- Reagents
- Rapid Test Kits
- ELISA Products
- Molecular Diagnostic Products
- Clinical Chemistry Solutions
The company has more than 15 years of experience in the diagnostics sector and serves over 150 national and international clients.
Its product portfolio includes:
- Haematology
- Point of Care Testing (POC)
- Rapid Testing
- ELISA Diagnostics
- Molecular Diagnostics
- Clinical Chemistry
Q-Line Biotech focuses on delivering affordable and high-quality diagnostic solutions in India and overseas markets.(ipo updates).
Q-Line Biotech IPO Market Lot
The minimum market lot for the IPO is 800 shares.
| Application Type | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lots | 800 Shares | ₹2,74,400 |
| Retail Maximum | 2 Lots | 800 Shares | ₹2,74,400 |
| S-HNI Minimum | 3 Lots | 1,200 Shares | ₹4,11,600 |
| S-HNI Maximum | 7 Lots | 2,800 Shares | ₹9,60,400 |
| B-HNI Minimum | 8 Lots | 3,200 Shares | ₹10,97,600 |
IPO Reservation Details
| Investor Category | Shares Offered | Reservation |
|---|---|---|
| Anchor Investors | 17,81,200 Shares | 28.48% |
| QIB (Ex Anchor) | 11,88,000 Shares | 19.00% |
| NII/HNI | 8,91,600 Shares | 14.26% |
| Retail Investors | 20,79,200 Shares | 33.25% |
Q-Line Biotech IPO Important Dates
| Event | Date |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Basis of Allotment | May 26, 2026 |
| Refund Initiation | May 27, 2026 |
| Credit to Demat Account | May 27, 2026 |
| Listing Date | May 29, 2026 |
| IPO Cut-Off Time | May 25, 2026 – 5 PM |
Anchor Investor Details
| Particulars | Details |
|---|---|
| Anchor Bidding Date | May 20, 2026 |
| Anchor Size | ₹61.10 Crores |
| Shares Offered | 17,81,200 Shares |
| 30-Day Lock-In Ends | June 22, 2026 |
| 90-Day Lock-In Ends | August 20, 2026 |
Promoters of Q-Line Biotech Limited
The promoters of the company are:
- Saurabh Garg
- Amita Garg
- Ayush Garg
- Ajay Kumar Mahanty
- Abhay Agrawal
| Particulars | Shares | Holding |
|---|---|---|
| Pre-Issue Holding | 1,70,74,999 Shares | 96.77% |
| Post-Issue Holding | 2,33,28,199 Shares | Updated After Listing |
Objects of the Issue
The company plans to use IPO proceeds for business growth and debt reduction.
| Purpose | Amount |
|---|---|
| Working Capital Requirements | ₹110 Crores |
| Repayment of Borrowings | ₹90 Crores |
| General Corporate Purposes | Remaining Amount |
The IPO proceeds may strengthen the company’s balance sheet and improve operational capabilities.
Q-Line Biotech Financial Report
The company has reported strong growth in revenue and assets over the years.
| Year | Revenue | Expenses | PAT | Assets |
|---|---|---|---|---|
| 2023 | ₹184.81 Cr | ₹154.97 Cr | ₹32.10 Cr | ₹251.58 Cr |
| 2024 | ₹206.45 Cr | ₹175.85 Cr | ₹34.44 Cr | ₹339.25 Cr |
| 2025 | ₹322.58 Cr | ₹261.43 Cr | ₹28.13 Cr | ₹455.49 Cr |
| Dec 2025 | ₹236.50 Cr | ₹186.96 Cr | ₹38.69 Cr | ₹561.34 Cr |
Financial Highlights
- Revenue increased from ₹206.45 Cr to ₹322.58 Cr
- Assets increased significantly
- Strong profitability despite higher operating expenses
- Strong diagnostic sector demand supports business growth
Q-Line Biotech IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 17.66% |
| ROCE | 23.74% |
| EBITDA Margin | 22.73% |
| PAT Margin | 8.97% |
| Debt to Equity Ratio | 0.87 |
| EPS | ₹28.63 |
| RoNW | 23.74% |
| NAV | ₹120.60 |
The company has healthy profitability margins and strong operational efficiency.
Peer Group Comparison
Currently, there are no directly listed comparable companies available in India.
Strengths of Q-Line Biotech IPO Market Rumors
1. Strong Healthcare Sector Presence
The company operates in the growing diagnostics and medical testing industry.
2. Strong Revenue Growth
The company reported significant growth in revenue over the years.
3. Diverse Product Portfolio
Q-Line Biotech offers a wide range of diagnostic and pathology products.
4. Strong Client Base
The company serves more than 150 domestic and international clients.
5. Expansion and Debt Reduction
IPO proceeds will support working capital and reduce borrowings.
Risks of the IPO Market Rumors
1. SME IPO Risk
SME IPOs generally involve higher volatility and lower liquidity.
2. Regulatory Risks
Healthcare and diagnostic businesses face strict compliance requirements.
3. Profit Decline in FY2025
Despite higher revenue, profit declined compared to FY2024.
4. Competitive Industry
The diagnostics sector remains highly competitive.
Q-Line Biotech IPO GMP
The Grey Market Premium (GMP) of the IPO may fluctuate daily depending on market sentiment and subscription demand. Investors should not rely solely on GMP while making investment decisions.
Should You Apply for Q-Line Biotech IPO?
Based on the company’s strong market presence, healthy financials, and expansion plans, the IPO appears attractive for long-term investors with moderate to high risk appetite.
Positive Factors
- Strong healthcare industry demand
- Healthy revenue growth
- Diversified product range
- Large client base
- Strong operational margins
Negative Factors
- SME IPO volatility
- Regulatory challenges
- Decline in net profit during FY2025
Long-term investors may consider this IPO after proper financial research and risk assessment.
IPO Lead Managers
- Hem Securities Ltd.
- Share India Capital Services Pvt. Ltd.
Company Address
Q-Line Biotech Ltd.
298-281, Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station,
Lucknow, Uttar Pradesh – 226012
Phone: +91 522-2435570
Email: compliance@qlinebiotech.com
Website: https://qlinebiotech.com/
IPO Registrar
Purva Sharegistry (India) Pvt. Limited
Phone: +91-022-23018261 / 23016761
Email: support@purvashare.com
Website: https://www.purvashare.com/investor-service/ipo-query
Q-Line Biotech IPO FAQs
What is Q-Line Biotech IPO?
Q-Line Biotech IPO is an SME IPO through which the company plans to raise approximately ₹214.48 crores.
When will Q-Line Biotech IPO open?
The IPO will open on May 21, 2026, and close on May 25, 2026.
What is Q-Line Biotech IPO Price Band?
The IPO price band is ₹326 to ₹343 per share.
What is Q-Line Biotech IPO Lot Size?
The minimum bid is 800 shares with an application amount of ₹2,74,400.
What is the Q-Line Biotech IPO Allotment Date?
The allotment date is May 26, 2026.
What is Q-Line Biotech IPO Listing Date?
The IPO will list on NSE SME on May 29, 2026.
Disclaimer
The information shared here is intended solely for educational and general awareness purposes. Any securities, investments, or IPO-related details mentioned should not be interpreted as financial advice or investment recommendations. Readers are encouraged to conduct their own independent research or seek guidance from a qualified financial professional before making investment decisions.
IPO-related updates are provided for informational use only. Market trends, past performance, or investor interest do not ensure future outcomes. We are not registered with SEBI. Investments in IPOs and the securities market involve inherent risks, and individuals should carefully evaluate their financial situation or consult a certified financial advisor before investing.
